Stilla is exhibiting at

Liquid Biopsy for Precision Oncology Summit

November 16-17 l Boston, MA

Exploring how a breadth of methods including ddPCR, single-cell genotypic & phenotypic analysis, in addition to pan-cancer, comprehensive NGS & tumor-informed assays are enabling detection screening, earlier diagnosis, resistance and recurrence monitoring – in turn facilitating quicker and more informed treatment decision-making in precision drug development.